Selegiline and mortality in Parkinson's disease

This publication has 31 references indexed in Scilit:

• Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease
  Acta Neurologica Scandinavica, 2009
• The effect of deprenyl and levodopa on the progression of Parkinson's disease
  Annals of Neurology, 1995
• l‐3,4‐Dihydroxyphenylalanine‐Induced Dopamine Release in the Striatum of Intact and 6‐Hydroxydopamine‐Treated Rats: Differential Effects of Monoamine Oxidase A and B Inhibitors
  Journal of Neurochemistry, 1994
• Chronic treatment of (-)deprenyl prolongs the life span of male fischer 344 rats. Further evidence
  Life Sciences, 1993
• Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
  BMJ, 1993
• Maintenance on l-deprenyl prolongs life in aged male rats
  Life Sciences, 1990
• Deprenyl Protects Dopamine Neurons from the Neurotoxic Effect of 1‐Methyl‐4‐Phenylpyridinium Ion
  Journal of Neurochemistry, 1985
• Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985
• Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors
  Nature, 1984
• The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1975